STERIS plc (STE) is a leading global provider of infection prevention products and services, with a market cap of approximately $25 billion. The company offers sterilization equipment, contract services, and consumables for hospitals, healthcare providers, and pharmaceutical manufacturers to ensure safe, sterile environments.

Over the past 52 weeks, STE stock has outperformed the S&P 500 Index, returning 20.2% compared to 12.3%. Year-to-date, shares have soared 23.9%. Additionally, STE has surpassed the Health Care Select Sector SPDR Fund’s 7.9% increase in the same period.

Following strong Q2 2026 results, STERIS saw a 6.9% increase in its stock price. The company reported adjusted EPS of $2.47 and revenue of $1.46 billion, with growth in all segments. STERIS raised its fiscal 2026 outlook, boosting adjusted EPS guidance to $10.15 – $10.30 and expected free cash flow to $850 million.

Analysts project STERIS’ adjusted EPS to grow by nearly 11% to $10.23 for the fiscal year ending in March 2026. The company has consistently met or exceeded consensus estimates in the last four quarters, earning a “Moderate Buy” consensus rating from analysts.

Morgan Stanley raised STERIS’ price target to $295 and maintained an “overweight” rating on August 8. With a mean price target of $286, representing a 12.3% premium to the current price, and a street-high target of $300, suggesting a 17.8% potential upside.

Read more at Yahoo Finance: Are Wall Street Analysts Bullish on STERIS Stock?